ILLUSTRATIVE CASE - A COMMON SCENARIO

A 65 year old man, with no past history of epilepsy or seizures and of weight 80kg, is admitted with sepsis. After a 5 minute generalized tonic-clonic seizure (GTCS) he is given 2mg of intravenous lorazepam. After multiple brief GTCS he is given a further 2 mg of intravenous lorazepam. He becomes obtunded. After a further 10 minutes when he has developed subtle left facial twitching, 1 g of phenytoin is infused over 30 minutes. After a further 15 minutes, by which time his GCS is 8/15, colleagues in anaesthetics are contacted with a view to transfer to the intensive care unit.

INTRODUCTION

Status epilepticus (SE) is the term used to describe an abnormally prolonged state of self-perpetuating and evolving seizure activity, specifically defined by time, as a 5 minute seizure or an episode of briefer seizures with reduced recovery of awareness in between seizures\(^1\).

SE can be convulsive or non-convulsive in type. Non-convulsive seizures represent states of various levels of altered awareness, associated with electroencephalographic (EEG) seizure activity, but without outwardly observable convulsive activity\(^2\). An important feature of convulsive seizures is their potential for evolution into non-convulsive seizures, where the patient can appear “post ictal” but is having electrical seizures, without obvious convulsive activity\(^3\). Other types of status epilepticus include simple partial status (with preserved awareness), complex partial status (with impaired consciousness) and myoclonic status (often associated with coma)\(^4\).

Records from antiquity describe SE, but it has only been in the last century that there have been major advances in its understanding and treatment\(^5\). Many significant questions remain about the pathophysiology and management of this medical emergency which carries a substantial morbidity and mortality. This paper will present the current understanding of SE, identifying gaps in our knowledge. The evidence base for the pharmacological management of SE will be reviewed.

CAUSES AND PROGNOSIS

In 50% of cases of SE no cause is identified. The common causes of SE are presented in Figure 1\(^6-12\). Most episodes of SE are secondary to old structural lesions (e.g. a past stroke), with acute cerebral insults including acute stroke, anoxia, toxic and metabolic causes and alcohol and drug withdrawal, accounting for a significant proportion of the remaining cases. Patients with epilepsy can develop SE for various reasons including reduced serum drug levels from poor adherence with treatment regimens, or the effects of intercurrent rate is between 7.6 and 39\(^\%\).\(^{13}\). The mortality rate is higher in the elderly at 38% compared to 14% for younger adults\(^{14}\). Over half of SE patients present with de novo seizures\(^7\) and approximately 10% will have recurrent episodes of SE\(^14\). Patients presenting with SE also have a higher likelihood of developing chronic epilepsy when compared to those who present with a first seizure, that does not fulfill the criteria for SE\(^15\).

EPIDEMIOLOGY

With an incidence of 6 to 41 per 100,000\(^\text{6-12}\) for convulsive SE, between 108 and 738 cases would be expected to occur in Northern Ireland each year. Incidence is bimodal, with peaks in infancy and in the elderly (>60). The overall case fatality
illnesses and fever. Table 1 summarises the more uncommon causes of SE identified in a recent systematic review.\textsuperscript{16}

**Table 1.**

| Category                  | Examples                                                                 |
|---------------------------|--------------------------------------------------------------------------|
| Autoimmune disorders      | Paraneoplastic disorders, Hashimoto encephalitis, anti NMDA receptor    |
|                           | encephalitis, anti VGKC encephalitis, antibody negative limbic encephalitis,|
|                           | paraneoplastic encephalitis                                              |
| Mitochondrial disease     | Mitochondrial diseases, MELAS, Leigh syndrome, MERRF, NARP, MBDGAE       |
| Viral infections          | HSV, bartonella, neurosyphilis, Q fever, HIV, measles, polio, CJD        |
| Seronegative disorders    | Chromosomal abnormalities (ring chromosome 20), inborn errors of metabolism (porphyria, etc), neurocutaneous syndromes, malformations of cortical development, Dravet syndrome, wrinkly skin syndrome. |
| Toxic                     | Intoxicants (beta lactams), antipsychotics, contrast media, cocaine, CO, |
|                           | acetylsalicylic acid, lead, petrol sniffing, chemotherapy, acute hypoxia, |
|                           | osmolality.                                                               |
| Medical conditions        | Multiple sclerosis, posterior reversible encephalopathy syndrome, Behcets disease, neuroleptic malignant syndrome, neurosurgery, electroconvulsive shock therapy. |

The outcome from SE is associated with the underlying aetiology. Anoxia is associated with a substantial mortality (72%). The lowest mortality is in patients with epilepsy who have provoked seizures, for example with low serum antiepileptic drug levels (mortality rate 4 - 8.6%)\textsuperscript{6} Age, duration of SE, whether there have been any prior episodes, depth of coma at presentation, and response to treatment have also been shown to be important.\textsuperscript{6, 14, 17, 18} The main modifiable factor is the duration of SE, highlighting the importance of urgent treatment. Duration of seizure activity has been shown to be an important predictor for mortality,\textsuperscript{19} with seizures lasting less than 30 minutes having a mortality of 2.6%, compared with 19% for those lasting more than 30 minutes.

**ACUTE PATHOPHYSIOLOGY - MECHANISMS OF STATUS EPILEPTICUS**

SE is an evolving state with changes in neuronal and synaptic chemistry and systemic physiology resulting in progressive pharmacological refractoriness. For the first 30 minutes physiological compensation occurs to meet the increased metabolic demands. Heart rate, blood pressure and serum glucose level are all elevated to minimize the risk of cerebral damage. After 30 minutes, compensation occurs with hypotension, hypoxia, metabolic acidosis, cardiac arrhythmias and cerebral auto-regulatory failure ensuing, all of which can lead to neuronal damage. Later complications include rhabdomyolysis, renal failure, pulmonary edema, increased intracranial pressure, and electrolyte disturbance.\textsuperscript{20}

Within seconds of the development of SE alterations occur in protein phosphorylation at various synapses, ion channel function and neurotransmitter release. Within minutes, receptor expression changes in favour of excitation as a result of progressive reduction in GABA (\(\gamma\)-aminobutyric acid) receptors and an increase in AMPA (\(\alpha\)-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and NMDA (N-methyl-D-aspartic acid) receptors. (Figure 2). By one hour there is an increase in excitatory neuropeptides. The excess in excitotoxic transmission is a suggested mechanism for neuronal cell death.\textsuperscript{21}

**CLINICAL EVALUATION OF STATUS EPILEPTICUS**

In evaluating the patient in SE, the ABC (Airway, Breathing, Circulation) approach to the management of any medical emergency should be employed. After airway and cardio-respiratory stability have been attained, hypoglycaemia must be excluded in all cases. Pabrinex may also be required at this stage, if the patient is at high risk of Wernicke’s encephalopathy.

**Table 2:**

| Clinical feature                  | Suggestive of Epileptic Seizures (Status Epilepticus) | Suggestive of Psychogenic non epileptic attacks (pseudoseizure) |
|-----------------------------------|------------------------------------------------------|---------------------------------------------------------------|
| Incongruent                        | onset: sudden onset. May have focal seizure activity at onset. | Suggestive of Psychogenic non epileptic attacks (pseudoseizure) |
|                                   | usual onset potentially lasting minutes. can have lead in of panic symptoms (which may not be localised by the patient). At times can start with sudden onset. | |
| Motor state                        | tone; then evolving into clonic movements. Muscle body stiffening, with some involuntary movements at times, can be focially largely during the ictus (atonic trio), bark arching, side to side head movements, undulating pelvic breathing. | |
| Evolution                          | a definite tonic phase, then clonic phase. As progresses the ictic movements become less pronounced, with hypstalgia or subtle twitching to the only manifestation. | |
| Localisation                       | at onset, they may look cultural cry as air is forced out past a tonic larynx. May occur in the middle of a seizure, crying and breathing are possible. | |
| Eyes                               | Eye closure is not typical. Eyes may be deviated. Pupils tend to be unresponsive. They are commonly forcibly closed. This is not always the case. Typically could be deviated away from the observer. Pupils are normal. | |
| Tongue                             | can have deep lateral tongue biting. Typically superficial front tip of the tongue bitten. | |
| Syndrome                           | present: Not present. No withdrawal from painful stimulus. | |
| Responsive?                       | none. No withdrawal from painful stimulus. | |
| Consistency                        | usually stereotyped seizure episodes. | |
| Recovery                           | delayed recovery after event, with amnesia. | |
| Nocturnal seizures                 | can happen. | |
| Stages of unconsciousness          | | |
| Injuries                           | common: fractures, head injuries, burns all reported. | |

Pseudostatus epilepticus (prolonged non-epileptic attacks) should be considered in all patients presenting with apparent SE. Differentiating between the two on clinical grounds alone can be difficult, even for experienced practitioners. Given the limited access to EEG, when the clinical diagnosis is not established beyond reasonable doubt, it is best to err on the side of caution and treat as SE. Clinical features that can help distinguish non-epileptic and epileptic seizures are...
detailed in Table 2.22, 23, 24, 25 The importance of making an accurate diagnosis is all too obvious, to prevent medicalising a psychological condition, to prevent iatrogenic morbidity from anticonvulsant medications, and to reduce morbidity and mortality associated with intubation and ICU stay26, 27.

Laboratory testing to include a full blood count, biochemistry, liver function tests, electrolytes, glucose, relevant serum antiepileptic drugs levels (to check compliance) and a toxicology screen are recommended as a minimum. Investigations should not delay treatment. In appropriate circumstances, where an infectious cause is suspected, lumbar puncture is necessary. SE can lead to a slightly raised cerebrospinal fluid white cell count28. All first presentations of SE should have emergent neuroimaging once the patient is stabilized, utilizing whatever modality is available locally. EEG is invaluable not only for confirming the diagnosis and planning treatment but in the patient who remains obtunded after a seizure, to distinguish a prolonged post ictal state from non-convulsive SE and other causes of reduced consciousness.

STOPPING STATUS EPILEPTICUS

Delays occur at various points in the management of SE, including time to presentation and initiation of first line treatment29. In order to minimise these and to reduce variability in practice, SE should be managed with a protocol which provides details on appropriate doses of medications to be given in a timely manner30. A simple protocol for the management of SE is given in Figure 3. More detailed guidelines have been published by various groups such as NICE31, EFNS32, and the American Society of Neurocritical Care33 as well as groups of international experts34.

Several clinical trials guide the early management of SE35, 36, 37, 38. They show that early use of benzodiazepines is important for controlling SE. They work by enhancing the inhibitory GABAergic system, and at higher concentrations limit sustained repetitive neuronal firing39. Lorazepam, diazepam and midazolam are the most frequently used.

Diazepam achieves early high brain concentrations and therefore has a very fast onset of action. Unfortunately, it quickly redistributes to fatty tissues, limiting clinical effectiveness to 20-30 minutes and often necessitating repeated dosing which has the potential to lead to accumulation due to its long elimination half-life. While diazepam and lorazepam are equivalent at achieving seizure control35, lorazepam is the drug of choice in early status due to its favorable pharmacokinetic profile, with a half-life of 12-24 hours. A recent prehospital study38 compared intramuscular (IM) midazolam and intravenous (IV) lorazepam. It demonstrated that patients received treatment quicker utilizing the IM approach, and that this lead to greater cessation of SE on arrival to the emergency department. Intravenous benzodiazepines have significant side effects including respiratory depression (3-10%), hypotension (<2%), and impaired consciousness (20-60%)39.

Second line therapies include phenytoin/fos-phenytoin, phenobarbital, valproate, levetiracetam and lacosamide. The best drug to use has not been conclusively demonstrated by a randomized controlled clinical trial.40 Phenytoin is the most commonly used second line drug in the United Kingdom. It should be given at a dose of 20mg/kg infused at a rate of 50mg/kg. Slower infusion rates are used if cardiac arrhythmia or hypotension occurs. A loading dose can also be given if the patient is taking phenytoin. If the patient presents in SE it is likely that they have a subtherapeutic serum level of phenytoin. Maximum cerebral concentrations are achieved towards the end of the infusion. Side effects include hypotension in 28-50%, bradyarrhythmias and ectopics in <2%. It is important to monitor drug levels after loading with phenytoin, to guide further dosing. Typically maintenance dose will be started the following day at 4-5mg/kg once daily 39, 40.

Other agents used in SE (off license indication) have certain advantages over phenytoin such as faster administration rates, fewer interactions, less side effects and better pharmacokinetics40. The second line agents are listed in Table 3 along with their doses, mean efficacy from the results of meta-analyses, side effects and mechanisms of action.

It is presently unclear if some patients should be given one second line drug, or should be rapidly escalated to an initial polytherapy approach, given the fact that treatment of SE becomes more difficult the longer it has occurred41. A multi-center blinded comparative randomized control trial using an adaptive design is in the process of being set up which seeks to guide the optimal second line drug choice42.

For those with epilepsy making sure that they get their regular AEDs in their usual doses at all times, given by whatever means possible (given by nasogastric tube or intravenously)
is also crucial. Maintaining therapeutic doses of any AEDs that have been commenced should also not be overlooked. Both are common reasons for failure to maintain control in those presenting with SE, where seizures have initially been successfully terminated. Treating the underlying cause whenever possible is also important if the best outcomes are to be achieved.

### Table 3.
Second line management of status epilepticus.

| Drug        | Mean Efficacy (%) | Dose          | ADRs                              | Mode of action                              |
|-------------|------------------|---------------|-----------------------------------|---------------------------------------------|
| Phenobarbital| 73.6%            | 20mg/kg IV up to 60mg/min | Respiratory depression, hypotension, severe sedation, tolerance and the potential for drug interactions | GABA potentiation                           |
| Phenothiazine| 75.7%            | 20mg/kg IV at 50mg/minute (50mg/minute if cardiovascular instability or elderly) | Cardiorespiratory risks (cardiac arrhythmia, hypotension, reduced cardiac output, the purple-glove syndrome) | Sodium channel modulation                   |
| Propofol    | 50.2%            | 25mg/min. Probably safe at 6 mg/kg/min | Hypnotional effects and somnolence, ataxia and agitation, sedation, memory impairment, diplopia, visual hallucinations | Minimal sedation, GABA, sodium channel modulation, sedation, WADA inhibition |
| Levobunolol| 50.2%            | 3mg/kg/min. Free of significant adverse-effect | GABA type A receptor antagonism, 2A | GABA potentiation                           |
| Lacosamide | 68.5%            | 200-400mg bolus over 5 minutes | Bradyarrhythmia, Pr interval prolongation | Sodium channel modulation                   |

### STATUS EPILEPTICUS IN THE INTENSIVE CARE UNIT

Refractory SE is the state when first and second line therapies have failed, usually 30 minutes into the SE episode. In hospital based series it occurs in 31 - 44% of cases, and has a mortality rate between 16 - 23%. It has been reviewed in several excellent recent articles.

Anaesthetic agents used are propofol, midazolam, thiopental or phenobarbital. These are outlined in Table 4 in detail. Often an antiepileptic drug is also given in a loading dose and uptitrated so that once weaning from anaesthetic agents is started there is a background effective antiepileptic agent. The choice of anaesthetic agents is based on small open trials, with no adequately powered prospective randomised controlled trial ever having been completed in this area. Decisions such as treatment duration and target of treatment (either clinical seizure suppression or EEG guided, such as suppression-burst suppression) are thus on an individual patient basis. Usually the patient will be anaesthetized for 12-24 hours and then the agents weaned slowly over a period of hours. If after the first wean there are further clinical or electrographic seizures they will require further anesthesia. This situation is then termed super refractory SE.

With regards the anaesthetic agents used in SE a number of safety points are worth highlighting. The main clinical concern with propofol is the risk of propofol infusion syndrome (PRIS). It is characterized by metabolic acidosis, cardiac disturbances, hypertriglyceridaemia, and rhabdomyolysis. The main risk factors appear to be dosage (>83mcg/kg/minute) and duration of therapy (>48hrs), and simultaneous vasopressor support. It carries a high mortality rate, at least in the early series, and calls for vigilance. The major limiting factors in barbiturate therapy are the risk of haemodynamic instability, immunosuppression, risk of gastrointestinal motility disturbance and nosocomial infection, particularly intestinal infection.

Oher general medical problems can befall the patient in ICU with SE. The main concerns include airway protection, aspiration related to the low GCS, cerebral hypoperfusion, and cardiac dysrhythmia. Hypertension can complicate the first 60 minutes of SE and it is worth bearing in mind that all parenteral anti-epileptic drugs will lower blood pressure, as will sedatives used for intubation. Positive pressure ventilation reduces preload and can also result in the patient ending up becoming hypotensive.

### Table 4.
Third line agents for status epilepticus.

| Drug           | Loading Dose | Maintenance Dose | ADRs                                      | Mode of action                                      |
|----------------|--------------|------------------|-------------------------------------------|------------------------------------------------------|
| Midazolam (midazolam paper in neurology) | 1-2mg/kg at 4mg/kg minute bolus | 0.5-1mg/kg/hour if required | Hypotension, hypothyrosis, increasing dose needed with time | GABA antagonist                                      |
| Propofol       | 0.1-0.5mg/kg | 0.5-2mg/kg/hour  | Hypotension, hypothyrosis, increasing dose needed with time | GABA antagonist                                      |
| Thiopental     | 10-25mg over 20-50iecs, 5-10mg bolus every 2-3 minutes to seizure control | 2-3mg/kg/hour if required | Accumulation, hypotension, and immunosuppression | GABA antagonist                                      |
| Phenytoin      | 14-36h       | 1-2h              | GABA potentiation                         | GABA antagonist                                      |

Various parenteral preparations of anticonvulsants are available for use in intensive care units, namely phenytoin, fosphenytoin, valproate, levetiracetam, and lacosamide. Care should be taken in the critically ill patient to ensure that phenytoin and valproate levels are interpreted correctly as often the albumin level is low. Simple conversion tools are available online to help with administration of these drugs (http://www.mdcalc.com/phenytoin-dilantin-correction-for-albumin-or-renal-failure/).

Multiple anti-epileptic drugs will often be tried if patients enter a super refractory state. The duration of anesthesia, using combinations of anaesthetic agents is often prolonged and at times periods of 1 week of anesthesia are used prior to attempting weaning. At this stage attention needs to be directed towards rarer causes of SE (Table 1). One potentially very treatable group of disorders is the immune encephalopathies. If there is any concern that the cause of SE is one of these disorders a trial of immunotherapy is warranted whilst waiting for corroborative evidence such as the results of autoantibody testing or patterns of abnormalities seen on detailed neuroimaging.

Other novel treatments include electroconvulsive therapy (ECT), surgical lesionectomy for example in patients with
complex partial status presumed to originate from an acute structural abnormality e.g. subdural haematoma, hypothermia, and other drugs such as ketamine, lidocaine, and isoflurane. The evidence base for these treatments is currently very limited. The outcome from refractory and super refractory SE is poor, with death in 35% and recovery to baseline in 35%. For those surviving, neurological disability can vary considerably. In one retrospective analysis it was shown that a prolonged duration of SE did not preclude a meaningful functional and cognitive recovery. It is not clear if progressive cognitive decline that can follow SE is due predominantly mainly to the underlying epileptic condition or the underlying aetiology of SE.

CONCLUSION FROM ILLUSTRATIVE CASE

The management of the patient in the illustrative case would have been improved by the use of an agreed protocol. After having been diagnosed as having early SE he should have been given 4 mg of lorazepam intravenously. Weighing 80 kg, he should then have been given an infusion of 1600mg of phenytoin, to be given over 32 minutes. If ten minutes after receiving the first dose of intravenous lorazepam he was still showing any signs of seizure activity he should have had a further 4mg of lorazepam, given intravenously. Having completed the infusion of phenytoin any further seizure activity should have prompted immediate referral to ICU.

REFERENCES

1. Lowenstein DH, B meilleure T, Macdonald RL. It’s time to revise the definition of status epilepticus. Epilepsia. 1999;40(1):120-2.
2. Meierkord H, Holtkamp M. Non-convulsive status epilepticus in adults: clinical forms and treatment. Lancet Neurol. 2007;6(4):329-39.
3. DeLorenzo RJ, Waterhouse EJ, Towne AR, Boggs JG, Ko D, DeLorenzo GA, et al. Persistent non-convulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia. 1998;39(8):833-40.
4. Sutter R, Kaplan PW, Electroencephalographic criteria for nonconvulsive status epilepticus: synopsis and comprehensive survey. Epilepsia. 2012;53(Suppl 3):1-51.
5. Shorvon S. The historical evolution of, and the paradigms shifts in, the therapy of convulsive status epilepticus over the past 150 years. Neurology. 2010;74(18):4093-40.
6. DeLorenzo RJ, Hauser WA, Towne AR, Boggs JG, Pellock JM, Penberthy L, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46(4):1029-35.
7. Hesdorffer DC, Logroscino G, Cascino G, Annersges JW, Hauser WA. Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology. 1998;50(3):735-41.
8. Coeytaux A, Jallon P, Galobardes B, Morabia A. Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR). Neurology. 2000;55(5):693-7.
9. Knake S, Rosena F, Vescov M, Oertel WH, Mueller HH, Wibart A, et al. Status Epilepticus Study Group Hessen (SESGH). Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia. 2001;42(6):714-8.
10. Wu Y, Shek DW, Garcia PA, Zhao S, Johnston SC. Incidence of status epilepticus in adults. Epilepsia. 2002;43(7):1070-76.
11. Vignatelli L, Tonon C, D’Alessandro R, Bologna Group for the Study of Status Epilepticus. Incidence and short-term prognosis of status epilepticus in adults in Bologna, Italy. Epilepsia. 2003;44:964-8.
12. Waterhouse E, and Kaplan P. (2011) The causes of convulsive status epilepticus in adults. In: Shorvon S, Andermann F, Guerrini, editors, The Causes of epilepsy., common and uncommon causes in adults and children. Cambridge: Cambridge University Press. p. 735.
13. Rossetti AO, Hurwitz S, Logroscino G, Bromfield EB. Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry. 2006;77(5):611-5.
14. Hesdorffer DC, Logroscino G, Cascino G, Annersges JW, Hauser WA. Risk of unprovoked seizure after acute symptomatic seizure: effect of status epilepticus. Ann Neurol. 1998;44(6):908-12.
15. Tan RY, Neligan A, Shorvon SD. The uncommon causes of status epilepticus: a systematic review. Epilepsy Res. 2010;91(2):111-22.
16. Neligan A, Shorvon SD. Prognostic factors, morbidity and mortality in tonic-clonic status epilepticus: a review. Epilepsia. 2011;53(1):1-10.
17. Sutter R, Kaplan PW, Rüegg S. Outcomes predictors for status epilepticus-what really counts. Nat Rev Neurol. 2013;9(9):525-34.
18. DeLorenzo RJ, Barnett LK, Towne AR, Waterhouse EJ, Boggs JG, Morton L, et al. Comparison of status epilepticus with prolonged seizures lasting from 10 to 29 minutes. Epilepsia. 1999;40(2):164-9.
19. Shorvon S. The management of status epilepticus. J Neurol Neurosurg Psychiatry. 2001;70(suppl 11):i22-i27.
20. Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 2006;5(3):246-56.
21. Malg menstrual K, Leuber M, Appleton R. Differential diagnosis of epilepsy. In: Shorvon S, Guerenn R, Cook M, Lhatoo S, editors. Oxford Textbook of epilepsy and epileptic seizures. Oxford Textbooks in Clinical Neurology. Oxford: Oxford University Press. p. 83.
22. Benbadis S. The differential diagnosis of epilepsy: a critical review. Epilepsy Behav. 2009;15(1):15-21.
23. LaFrance JC, Baker GA, Duncan R, Goldstein LH, Reuber M. Minimum requirements for the diagnosis of psychogenic nonepileptic seizures: a staged approach: a report from the International League Against Epilepsy Nonepileptic Seizures Task Force. Epilepsia. 2013;54(11):2005-18.
24. R Nandhagopal. Generalised convulsive status epilepticus: an overview. Postgrad Med J. 2006;82(973):723-32.
25. Reuber M, Baker GA, Gill R, Smith DF, Chadwick DW. Failure to recognize psychogenic nonepileptic seizures may cause death. Neurology. 2004;62(5):834-5.
26. Pakalnis A, Drake ME, Phillips B. Neuropsychiatric aspects of psychogenic status epilepticus. Neurology. 1991;41(7):1104-6.
27. Dart E, Hauser WA. Pleocytosis after status epilepticus. Neurology. 1992;45(2):190-3.
28. Hillman J, Lehtimaki K, Peltola J, Liimatainen S. Clinical significance of treatment delay in status epilepticus. Int J Emerg Med. 2013;6(1):6.
29. Analysis of the delay components in the treatment of status epilepticus. Kampii L, Mustonen H, Soinila S. Neurocrit Care. 2013;19:10-8.
30. NICE Clinical Guideline; 137. The Epilepsies: diagnosis and management of the epilepsies in adults in primary and secondary care. London: National Institute for Health and Care Excellence; 2012.
31. Meierkord H, Boon P, Engelsen B, Göcke K, Shorvon S, Tinuper P, et al. European Federation of Neurological Societies. Guideline on the
management of status epilepticus in adults. Eur J Neurol. 2010;17(3):348–55

33. Brophy GM, Bell R, Claassen J, Allredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3-23.

34. Jones S, Phal C, Trinka E, Nashef L. A protocol for the inhospital emergency drug management of convulsive status epilepticus in adults. Pract Neurol. 2014;14(3):194-197

35. Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. Eur J Neurol. 2010;17(3):348–55

36. Treiman DM, Meyers PD, Walton NY, Collins JC, Rowan AJ, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998;339(12):792–8.

37. Alldredge BK, Gelb AM, Isaacs M, Corry MD, Allen F, Ulrich SK et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001;345(9):631-7.

38. Silbergleit R, Durkalski D, Lowenstein D, Conwit R, Pancioli A, Palesch Y, NETT Investigators. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366(7):591-600.

39. Lowenstein DH, Allredge BK. Status epilepticus. N Engl J Med. 1998;338(14):970-6.

40. Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure. 2014;23(3):167-74.

41. Wasterlain C, Baldwin R, Niquet J, Suchomelova L. Sequential versus simultaneous polytherapy in the treatment of status epilepticus. Neurology. 2014;82(10 Suppl):S29.004.

42. Established Status Epilepticus Treatment Trial (ESETT) Hannah R. Cock on behalf of the ESETT Group. Epilepsia 2-11; 52(Suppl. 8):50–52

43. Rossetti A.O., Lowenstein DH. Management of refractory status epilepticus in adults. Still more questions than answers. Lancet neurology 2011;10:922-930.

44. Walker M. Status epilepticus on the intensive care unit. J Neurol 2003;250:401-406

45. Ziai W, Kaplan P. Seizures and status epilepticus in the intensive care unit. Seminars in Neurology 2008;28:668-681

46. Rossetti A. Which anesthetic should be used in the treatment of refractory status epilepticus? Clinical aspects of status epilepticus. Epilepsia 2007;48:52-55

47. Claassen J, Hirsch L, Emerson R, Mayer S. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002;43:146-153

48. Shorvon S. The treatment of status epilepticus. Curr Opin Neurol. 2011;24(2):165–70

49. Prabhakar H, Bindra A, Singh GP, Kalaivani M. Propofol versus thiopental sodium for the treatment of refractory status epilepticus. Cochrane Database of Systematic Reviews; 2012(8): 009202.

50. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134(Pt 10):2802-18.

51. Hwang WS, Gwak HM, Seo DW. Propofol infusion syndrome in refractory status epilepticus. J Epilepsy Res. 2013;3(1):21-7.

52. Shovon S, Ferlisi M. The outcome of therapies in refractory and superrefractory convulsive status epilepticus. Brain. 2012;135(Pt 8):2314-28.

53. Copper AD. Britton JW, Rabenstein AA. Functional and cognitive outcome in prolonged refractory status epilepticus. Arch Neurol. 2009;66(12):1505-9.

54. Helmstaedter C. Cognitive outcome of status epilepticus in adults. Epilepsia. 2007;48(Suppl 8):85-90.